Xiaomi Li
Beijing, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications
Dose-dependent efficacy of CX1003 in NSCLC immunotherapy: High dose for T cell response, low dose for apoptosis.
Journal: International immunopharmacology
Published: June 15, 2025
A Phase II Trial of Perioperative Camrelizumab Plus Neoadjuvant Chemotherapy in Resectable Stage IIB-IIIB Lung Squamous Cell Carcinoma.
Journal: MedComm
Published: May 16, 2025
Establishment and validation of a convenient and efficient screening tool for active pulmonary tuberculosis in lung cancer patients based on common parameters.
Journal: Therapeutic advances in medical oncology
Published: February 08, 2025
The IASLC uncertain resection, general overview, current evidence, and future prospects: a systematic review and meta-analysis.
Journal: Therapeutic advances in medical oncology
Published: December 08, 2024
A cohort study of circulating biomarkers to predict the efficacy and prognosis of immune combination therapy in non-small-cell lung cancer.
Journal: The oncologist
Published: November 24, 2024
Navigating the landscape of neoadjuvant immunotherapy for NSCLC: progress and controversies.
Journal: Therapeutic advances in medical oncology
Published: September 25, 2024
Immuno-combined treatment versus radio-combined treatment in limited-stage small-cell lung cancer.
Journal: Therapeutic advances in medical oncology
Published: June 20, 2024
Easily applicable predictive score for MPR based on parameters before neoadjuvant chemoimmunotherapy in operable NSCLC: a single-center, ambispective, observational study.
Journal: International journal of surgery (London, England)
Published: October 30, 2023
Development of a Multivariate Prognostic Model for Lenvatinib Treatment in Hepatocellular Carcinoma.
Development of a Multivariate Prognostic Model for Lenvatinib Treatment in Hepatocellular Carcinoma.
Journal: The oncologist
Published: October 10, 2022
Prognostic model of immune checkpoint inhibitors combined with anti-angiogenic agents in unresectable hepatocellular carcinoma.
Journal: Frontiers in immunology
Published: October 02, 2022
Last Updated: 09/26/2026